Know Cancer

forgot password

Metabolic Syndrome as Modifiable Risk Factor for Breast Cancer

35 Years
80 Years
Open (Enrolling)
Metabolic Syndrome as Breast Cancer Risk Factor

Thank you

Trial Information

Metabolic Syndrome as Modifiable Risk Factor for Breast Cancer

A total of 777 patients have been enrolled in our nested case-control study. 293 of them
operated for breast cancer (cases) and 484 healthy women (controls) have been recruited
between 2008 and 2009 to take part to our study for evaluating the association between MS
and breast cancer. Liver or renal disease, thyroid pathology and coronary artery disease
were considered exclusion criteria. After obtaining informed consent, signing the
authorization to be enrolled in the study, for each woman anthropometric features were
measured, including weight in kilograms, height in meters, waist and hip circumference,
arterial blood pressure was taken and venous blood was collected [15]. BMI (kg/m²) was
calculated from weight and height values according to World Health Organization
classification (< 25 kg/m²= underweight/normal, ≥ 25 kg/m²= overweight/obese), waist and hip
ratio (WHR) was obtained from waist and hip circumference, measuring the smallest
circumference of both to discriminate between android and gynoid fat distribution [22]. From
blood samples fasting plasma glucose, HDL-C, triglyceride, uric acid, insulin and
testosterone levels were assessed. Fasting plasma glucose, HDL-C and triglyceride were
measured according to NCEP ATP III criteria. The normal range for uricemia was 2.6-6.0
mg/dl. Insulin levels were defined in normal range when between 5 and 25 mcU/ml, whereas ≥
25 mcU/ml were considered hyperinsulinemia. Testosterone levels were considered in the
normal range when 0.20-1.20 ng/ml. Levels > 1.20 ng/ml were considered indicative of
hyperandrogenic status. Women were asked to answer a questionnaire about chronic diseases,
tobacco use, alcohol abuse, food intake, physical activity grade, parity, age of menarche,
menopausal status, oral contraceptive use, hormonal therapy use, personal and familial
history of cancer. According to the NCEP ATP III [10], women presenting three disorders were
diagnosed with low grade MS [5], whereas women presenting more than three disorders (four or
five) were diagnosed with high grade MS. Chi-squared test and logistic regression analyses
(OR and 95% CI) were used to confirm the association between MS and breast cancer and to
calculate the risk. Statistical significance was considered at P < 0.05.

Inclusion Criteria:

- healthy women

- women operated for breast cancer

Exclusion Criteria:

- Liver or renal disease,

- thyroid pathology

- coronary artery disease

Type of Study:


Study Design:

Observational Model: Case Control, Time Perspective: Retrospective


Italy: National Institute of Health

Study ID:




Start Date:

January 2008

Completion Date:

Related Keywords:

  • Metabolic Syndrome as Breast Cancer Risk Factor
  • Metabolic Syndrome obesity visceral adiposity breast cancer
  • Breast Neoplasms
  • Metabolic Syndrome X